Quantum BioPharma, a biopharmaceutical company listed on NASDAQ (QNTM), is committed to developing innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders. Their subsidiary, Lucid Psycheceuticals Inc., focuses on advancing Lucid-MS, a novel compound that has demonstrated efficacy in preventing and reversing myelin degradation, a key factor in multiple sclerosis. Additionally, Quantum BioPharma introduced unbuzzd™ and licensed its OTC version to Celly Nutrition Corp., while retaining a significant ownership stake and royalty agreements. Moreover, through FSD Strategic Investments Inc., Quantum BioPharma maintains a diverse portfolio of strategic investments secured by real estate assets.Collaborating with iNGENū CRO, Quantum BioPharma is embarking on a groundbreaking clinical trial in Australia to address Chronic Nociplastic Pain in Mast Cell Activation Syndrome (MCAS) patients. This partnership signifies a strategic move towards advancing biotech solutions for challenging medical conditions. The synergistic efforts of Quantum BioPharma and iNGENū CRO highlight a commitment to pioneering research and development in the biopharmaceutical landscape. As the trial progresses, the outcomes may provide valuable insights into potential treatment options for individuals suffering from chronic pain associated with MCAS. This collaboration exemplifies a proactive approach to addressing unmet medical needs and underscores the importance of strategic partnerships in driving innovation within the biotech industry.
Read more from finance.yahoo.com
